DYN

Dyne Therapeutics Inc · NASDAQ

Sector Health Technology
Industry Biotechnology
Website dyne-tx.com
Employees(FY) 136
ISIN US26818M1080

Performance

-6.33%

-19.17%

-34.11%

-27.63%

+80.38%

YTD

+104.87%

Profile

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Advanced Technical Analysis

Technical Analysis of DYN 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score of 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of DYN

Stock Rank

Recent News & Updates

2024-12-13 07:52
Baird Initiates Dyne Therapeutics at Outperform With $46 Price Target(MT Newswires)
2024-11-26 06:22
RBC Initiates Dyne Therapeutics at Outperform, Speculative Risk With $45 Price Target(MT Newswires)
2024-11-22 06:43
Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts(Insider Monkey)
2024-11-12 09:11
Dyne Therapeutics' Q3 Loss Narrows(MT Newswires)
2024-11-12 07:30
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update(GlobeNewswire)
2024-11-11 18:30
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-11-07 03:15
Dyne Therapeutics to Present at Upcoming Investor Conferences(Globenewswire)
2024-10-24 05:26
JPMorgan Downgrades Dyne Therapeutics to Neutral From Overweight, Adjusts Price Target to $35 From $43(MT Newswires)
2024-10-09 07:30
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases(GlobeNewswire)
2024-10-08 19:30
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE Platform to Address Underlying Causes of Neuromuscular Diseases(Globenewswire)
2024-10-07 17:32
Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now(Insider Monkey)
2024-09-23 08:56
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference(GlobeNewswire)
2024-09-22 20:56
Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference(Globenewswire)
2024-09-19 17:00
Dyne Therapeutics Insider Sold Shares Worth $308,864, According to a Recent SEC Filing(MT Newswires)
2024-09-06 06:39
CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More Shares(Simply Wall St.)
2024-09-05 11:15
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More(Zacks)
2024-09-04 17:46
Dyne Therapeutics Insider Bought Shares Worth $1,057,216, According to a Recent SEC Filing(MT Newswires)
2024-09-04 12:58
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down(Zacks)
2024-09-04 08:15
High-dose Spinraza meets study goal; Top Dyne executives exit(BioPharma Dive)
2024-09-03 16:10
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building(Investor's Business Daily)
2024-09-03 12:37
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy(Benzinga)
2024-09-03 12:30
Dyne Therapeutics Duchenne Muscular Dystrophy Drug Study Shows Improvements -- Shares Tumble(MT Newswires)
2024-09-03 06:31
Dyne Therapeutics Announces Key Leadership Appointments(GlobeNewswire)
2024-09-03 06:30
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts(GlobeNewswire)
2024-09-02 18:31
Dyne Therapeutics Announces Key Leadership Appointments(Globenewswire)
2024-09-02 18:30
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts(Globenewswire)
2024-08-29 07:30
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference(GlobeNewswire)
2024-08-28 19:30
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference(Globenewswire)
2024-08-13 05:23
Chardan Adjusts Price Target on Dyne Therapeutics to $50 From $42, Maintains Buy Rating(MT Newswires)
2024-08-13 04:15
Dyne Therapeutics Q2 Loss Narrows(MT Newswires)

Page 1 of 8

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.